Search Follow us
Refine By

Stock Exchange

Market Cap (m)

Analyst

Type of Publication

international stem

1 - 11 of 11
Sort by: popularity | newest
Page  of 1
International Stem Cell

Strong biomedical sales and new clinical data

Update | Pharmaceuticals & healthcare | 04 Dec 2018

International Stem Cell (ISCO) reported Q318 revenues of $3.2m, up 73.0% compared to Q317 mainly due to the biomedical business, which had quarterly revenues of $2.8m, up 112.8% year-on-year. Additionally, the company reported updated data from the Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). At the six-month time point, the percentage OFF-Time, a key endpoint for PD treatment, decreased an average of 49% for the second cohort of patients, compared to 24% for the first, with four patients in each cohort.

International Stem Cell

Biomedical sales more than double

Update | Pharmaceuticals & healthcare | 20 Aug 2018

International Stem Cell (ISCO) reported Q218 revenues of $3.0m, up 72.4% compared to Q217 mainly due to the biomedical business, which had quarterly revenues of $2.7m, up 103.1% compared to the same quarter last year. The operating profit of the biomedical business also increased substantially, up 139.6% to $1.1m. With regard to the Phase I trial of ISC-hpNSC in Parkinson’s disease (PD), the company has successfully dosed the first patient of the third cohort and expects to release interim six-month results from the second cohort in Q318.

International Stem Cell

Third cohort ready to go

Update | Pharmaceuticals & healthcare | 06 Jun 2018

International Stem Cell (ISCO) recently announced that the data safety monitoring board for its Phase I trial of ISC-hpNSC in Parkinson's disease (PD) has authorized the enrollment of the third cohort of four patients. The study has already enrolled eight patients at the 30m and 50m cell levels and will now enroll patients at the 70m cell level. Recruitment will begin immediately. The company announced interim six-month results from the first cohort of four patients in November and we expect additional data from this as well as the second cohort in the coming months.

International Stem Cell

Moving forward in Parkinsons and TBI

Outlook | Pharmaceuticals & healthcare | 14 May 2018

International Stem Cell (ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson’s disease (PD). In November, the company presented interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in PD. Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders.

International Stem Cell

Interim Parkinson's data

Update | Pharmaceuticals & healthcare | 03 Jan 2018

International Stem Cell recently announced interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders. The trial is continuing and the second cohort is almost enrolled, with the third patient of four recently undergoing surgical implantation. The study will enroll 12 patients at three dosing regimens (30-70m cells).

International Stem Cell

Green light for second cohort

Update | Pharmaceuticals & healthcare | 24 May 2017

International Stem Cell recently announced that the data safety monitoring board (DSMB) for its Phase I trial of ISC-hpNSC in Parkinson's disease (PD) has authorized the enrollment of the second cohort of four patients. The study will ultimately enroll 12 patients at three dosing regimens (30m-70m cells) with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.

International Stem Cell

Dosing of first cohort complete

Update | Pharmaceuticals & healthcare | 27 Apr 2017

International Stem Cell recently announced that the first cohort of four patients in its Phase I trial in Parkinson's disease (PD) had successfully undergone intracranial transplants of ISC-hpNSC. The study will ultimately enroll 12 patients at three dosing regimens (30m-70m cells) with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.

International Stem Cell

Phase I progressing

Update | Pharmaceuticals & healthcare | 14 Dec 2016

International Stem Cell recently announced that the first two patients in its Phase I trial in Parkinson’s disease (PD) had successfully undergone intracranial transplants of ISC-hpNSC without complications. The study will enroll 12 patients at three dosing regimens with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.

International Stem Cell

First patient dosed in Phase I trial

Update | Pharmaceuticals & healthcare | 02 Aug 2016

International Stem Cell announced in July 2016 that it had dosed the first patient in the Phase I dose escalation study examining its neural stem cell product ISC-hpNSC for the treatment of moderate to severe Parkinson's disease. The study will enrol 12 patients at three dosing regimens with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.

International Stem Cell

Seeking a better treatment for Parkinson's

Initiation | Pharmaceuticals & healthcare | 16 May 2016

International Stem Cell (ISCO) is an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson's disease (PD). In addition, ISCO sells skincare and biomedical supplies to the market, generating $8m in sales and $1.7m in underlying operating profit in 2015. The commercial businesses provide a floor under ISCO's current valuation, creating an essentially free option on the PD candidate.

StemCells

Critical juncture in spinal cord injury

Update | Pharmaceuticals & healthcare | 05 Feb 2016

StemCells has reached a critical juncture in its development program with a highly encouraging interim analysis of its Phase II PATHWAY study pointing to promising efficacy in cohort 1 of its human central nervous system stem cells (HuCNS-SC) in lead indication spinal cord injury (SCI). Given limited financial resources, StemCells is realigning operations to focus efforts on the internal funding for key pivotal Phase III SCI trials. New group leadership by way of a recently announced change in CEO comes on the heels of the current company reorganization.